tolcapone (Tasmar)

05/01/2010 - "Other efficacy variables (Unified Parkinson's Disease Rating Scale II, III, and IVb and Investigator's Global Assessment scores) improved significantly after switching to tolcapone. "
01/01/2010 - "Adjunctive tolcapone treatment was associated with statistically significant improvement in QOL in fluctuating Parkinson's disease patients. "
05/01/1998 - "With 200 mg tolcapone tid, unified Parkinson's disease rating scale motor and total scores were significantly reduced, and quality of life (sickness impact profile) scores were significantly improved. "
10/01/1997 - "With 200 mg tolcapone tid, unified Parkinson's disease rating scale motor and total scores were significantly reduced, and quality of life (sickness impact profile) scores were significantly improved. "
01/01/2014 - "Under routine practice conditions, tolcapone was shown to be safe and effective in patients with Parkinson disease. "

05/01/1998 - "Tolcapone appears to be beneficial in the treatment of patients with parkinsonism who have not yet developed motor fluctuations."
09/01/1997 - "Tolcapone appears to be beneficial in the treatment of patients with parkinsonism who have not yet developed motor fluctuations."
04/01/2006 - "(4) Placebo-controlled trials show that first-line treatment with tolcapone 100 mg to 200 mg 3 times a day reduces the duration of motor freezing ("off") periods, but the global impact of tolcapone on parkinsonism appears to be limited. "
03/01/2000 - "Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism."
03/01/2000 - "The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times daily for 6 weeks. "

12/01/2009 - "Tolcapone could be potentially useful in the treatment of conditions with deficient sensorimotor gating and working memory such as schizophrenia and prodromal states but only in a genotype-specific manner."
04/01/2011 - "It will soon be understood if tolcapone represents one of the first hypothesis-driven, biology-based, genotype-specific, targeted treatments of cognitive and negative symptoms of schizophrenia."
04/01/2011 - "Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia."
06/09/2004 - "The interaction between clozapine and tolcapone may have implications for the treatment of schizophrenia."

05/01/1998 - "Dyskinesia developed or worsened in 18% of patients receiving placebo, in 51% receiving tolcapone 100 mg tid, and in 64% receiving 200 mg tid, with most cases occurring within the first 30 days of the study. "
10/01/1997 - "Dyskinesia developed or worsened in 18% of patients receiving placebo, in 51% receiving tolcapone 100 mg tid, and in 64% receiving 200 mg tid, with most cases occurring within the first 30 days of the study. "
01/01/2000 - "This may represent one cause for the occurrence of dyskinesia previously early in the course of treatment with tolcapone."
02/01/1998 - "Dyskinesias may increase in frequency and severity in patients already having dyskinesias and these may appear for the first time after adding tolcapone in patients at risk. "
06/01/1995 - "The intensity in dyskinesias was increased by 400 mg of tolcapone. "

04/01/2000 - "Update on "open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder"."
08/01/1999 - "Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder."